{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:21:15Z","timestamp":1787314875225,"version":"build-2736575974"},"reference-count":123,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Transthyretin amyloidosis (ATTR) is a rare disease that results in amyloid fibril misfolding and deposition in multiple organs, including the heart, leading to the development of ATTR cardiomyopathy (ATTR\u2010CM), which is associated with poor outcomes. In the last decade, several disease\u2010modifying medications are in advanced stages of clinical development or have been approved to treat ATTR\u2010CM. The purpose of this review is to critically evaluate clinical trial data investigating the use of approved and investigational medications for the treatment of ATTR\u2010CM. We performed a comprehensive literature search via PubMed and EMBASE to identify randomized controlled trials evaluating medications for the treatment of ATTR\u2010CM published through August 2024. This narrative review describes the pathophysiology of ATTR\u2010CM, highlights important screening and diagnostic work\u2010up, and summarizes the existing clinical evidence resulting from our literature search. Several classes of disease\u2010modifying medications are in development for ATTR\u2010CM. The tetramer stabilizers and transthyretin silencers have proven to be the most effective therapies to date. Tafamidis and acoramidis are currently approved for ATTR\u2010CM while vutrisiran approval for ATTR\u2010CM may be forthcoming. Other disease\u2010modifying medication classes in development include antisense oligonucleotides, gene editing therapies, and monoclonal antibodies. However, several unmet needs exist including the lack of cost\u2010effectiveness due to the extremely high acquisition costs of these medications. Disease\u2010modifying medications approved and in development to treat ATTR\u2010CM offer hope for patients with this disease, but their lack of affordability is the biggest barrier to their use.<\/jats:p>","DOI":"10.1002\/phar.4639","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T08:13:47Z","timestamp":1734941627000},"page":"124-144","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Disease\u2010modifying therapies for amyloid transthyretin cardiomyopathy: Current and emerging medications"],"prefix":"10.1002","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2515-3081","authenticated-orcid":false,"given":"Erika L.","family":"Hellenbart","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice University of Illinois Chicago  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0981-1358","authenticated-orcid":false,"given":"Heather J.","family":"Ipema","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice University of Illinois Chicago  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4925-838X","authenticated-orcid":false,"given":"Mary C.","family":"Rodriguez\u2010Ziccardi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Cardiology University of Illinois Chicago  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0539-3558","authenticated-orcid":false,"given":"Hema","family":"Krishna","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Cardiology University of Illinois Chicago  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9374-8012","authenticated-orcid":false,"given":"Robert J.","family":"DiDomenico","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice University of Illinois Chicago  Chicago Illinois USA"},{"name":"Center for Pharmacoepidemiology and Pharmacoeconomic Research University of Illinois Chicago  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,12,23]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.024438"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.11.022"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.121.318187"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.3109\/07853890.2015.1068949"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/07853890701842988"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx350"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv338"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000792"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0065-3233(08)60321-6"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.286.5446.1888"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvac119"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra023144"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1161\/circheartfailure.109.910455"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2016.2839"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.07.092"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.3109\/03009734.2014.895786"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.9236"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2014.07.026"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2019.04.010"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/hci.0000000000000029"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1161\/hci.0000000000000030"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.04.022"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1161\/circheartfailure.120.008225"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1161\/circheartfailure.119.006075"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.116.021612"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.carpath.2016.07.001"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2300757"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409134"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805689"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.01.036"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2020.06.007"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.12.012"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2020.05.015"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14188"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3198"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.03.429"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2021.06.007"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2019.1620724"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.10.079"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2020.07.034"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.63.6.1285"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2305434"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.03.012"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506120600960882"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.283815"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7133.2012.00303.x"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2019.1593133"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.3109\/13506129.2014.997872"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2019.11.024"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2021.2000388"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.789"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1159\/000525883"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2019.01.493"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2023.4147"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2022.5251"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2024.02.007"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2027"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.008193"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3190"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2020.09.037"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.700"},{"key":"e_1_2_9_63_1","unstructured":"Attruby (acoramidis) prescribing information. Palo Alto: BridgeBio Pharma Inc.2024. Accessed November 25 2024.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/216540s000lbl.pdf"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2023.10.251"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.124.072771"},{"key":"e_1_2_9_66_1","unstructured":"Attruby (acoramidis) a near complete TTR stabilizer (\u226590%) approved by FDA to reduce cardiovascular death and cardiovascular\u2010related hospitalization in ATTR\u2010CM patients. Palo Alto: BridgeBio Pharma Inc.2024. Accessed November 27 2024.https:\/\/bridgebio.com\/news\/attruby\u2010acoramidis\u2010a\u2010near\u2010complete\u2010ttr\u2010stabilizer\u2010\u226590\u2010approved\u2010by\u2010fda\u2010to\u2010reduce\u2010cardiovascular\u2010death\u2010and\u2010cardiovascular\u2010related\u2010hospitalization\u2010in\u2010attr\u2010cm\u2010patients\/"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10787"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2019.1597702"},{"key":"e_1_2_9_69_1","unstructured":"Tasmar (tolcapone) prescribing information. Bridgewater: Bausch Health US LLC.2020. Accessed September 25 2024.https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=a0e47a9d\u201078e7\u20104523\u2010983a\u2010aa259f221736"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.122.001107"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1124\/pharmrev.123.000815"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716153"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2022.2091985"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716793"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.18688"},{"key":"e_1_2_9_76_1","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13154"},{"key":"e_1_2_9_77_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15468"},{"key":"e_1_2_9_78_1","unstructured":"Onpattro (patisiran) prescribing information. Cambridge: Alnylam Pharmaceuticals Inc.2023. Accessed September 25 2024.https:\/\/www.alnylam.com\/sites\/default\/files\/pdfs\/ONPATTRO\u2010Prescribing\u2010Information.pdf"},{"key":"e_1_2_9_79_1","unstructured":"Amvuttra (vutrisiran) prescribing information. Cambridge: Alnylam Pharmaceuticals Inc.2023. Accessed September 25 2024.https:\/\/www.alnylam.com\/sites\/default\/files\/pdfs\/amvuttra\u2010us\u2010prescribing\u2010information.pdf"},{"key":"e_1_2_9_80_1","unstructured":"Tegsedi (inotersen) prescribing information. Waltham: Akcea Therapeutics Inc.2024. Accessed September 25 2024.https:\/\/tegsedihcp.com\/pdf\/prescribing\u2010information.pdf"},{"key":"e_1_2_9_81_1","unstructured":"UpToDate. Philadelphia: Wolters Kluwer. Accessed on September 10 2024."},{"key":"e_1_2_9_82_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.035831"},{"key":"e_1_2_9_83_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartjsupp\/suae036.002"},{"key":"e_1_2_9_84_1","first-page":"1268","article-title":"Long\u2010term safety and efficacy of patisiran: global open\u2010label extension 24\u2010month data in patients with hereditary transthyretin\u2010mediated amyloidosis","volume":"27","author":"Adams D","year":"2020","journal-title":"Eur J Neurol"},{"key":"e_1_2_9_85_1","doi-asserted-by":"publisher","DOI":"10.1161\/circ.148.suppl_1.13273"},{"key":"e_1_2_9_86_1","unstructured":"Alnylam announces receipt of complete response letter from U.S. FDA for supplemental new drug application for Patisiran for the treatment of the cardiomyopathy of ATTR amyloidosis.2023.https:\/\/investors.alnylam.com\/press\u2010release?id=27741"},{"key":"e_1_2_9_87_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3138"},{"key":"e_1_2_9_88_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-019-06919-4"},{"key":"e_1_2_9_89_1","unstructured":"Alnylam pharmaceuticals discontinues Revusiran development.2016.https:\/\/investors.alnylam.com\/press\u2010release?id=15771"},{"key":"e_1_2_9_90_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/suaa106"},{"key":"e_1_2_9_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrtlng.2020.02.008"},{"key":"e_1_2_9_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(18)31199-9"},{"key":"e_1_2_9_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(19)31516-5"},{"key":"e_1_2_9_94_1","unstructured":"Tegsedi (inotersen) for healthcare professionals. Accessed September 12 2024.https:\/\/tegsedihcp.com"},{"key":"e_1_2_9_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2023.11.016"},{"key":"e_1_2_9_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2023.101741"},{"key":"e_1_2_9_97_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107454"},{"key":"e_1_2_9_98_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2412309"},{"key":"e_1_2_9_99_1","unstructured":"GillmoreJD TaubelJ GaneE et\u00a0al.First\u2010in\u2010human in\u00a0vivo CRISPR\/Cas9 editing of the TTRGene by NTLA\u20102001 in patients with transthyretin (ATTR) amyloidosis with cardiomyopathy. Presented at: American Heart Association Scientific Sessions Chicago2022."},{"key":"e_1_2_9_100_1","unstructured":"First patient dosed in Phase I Clinical Trial of YOLT\u2010201.2024. Accessed September 25 2024.https:\/\/www.yoltx.com\/news\/press\u2010release\/65"},{"key":"e_1_2_9_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2024.101207"},{"key":"e_1_2_9_102_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.26"},{"key":"e_1_2_9_103_1","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-8-74"},{"key":"e_1_2_9_104_1","doi-asserted-by":"publisher","DOI":"10.3109\/13506129.2012.678508"},{"key":"e_1_2_9_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2019.01.006"},{"key":"e_1_2_9_106_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2016.1269739"},{"key":"e_1_2_9_107_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S96893"},{"key":"e_1_2_9_108_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-015-0826-3"},{"key":"e_1_2_9_109_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-012-0463-z"},{"key":"e_1_2_9_110_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-010-0142-x"},{"key":"e_1_2_9_111_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartjsupp\/suad079"},{"key":"e_1_2_9_112_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303765"},{"key":"e_1_2_9_113_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504942"},{"key":"e_1_2_9_114_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan3128"},{"key":"e_1_2_9_115_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02405-7"},{"key":"e_1_2_9_116_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-021-02407-6"},{"key":"e_1_2_9_117_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.045093"},{"key":"e_1_2_9_118_1","unstructured":"WasfyJH WinnAN TouchetteDR et\u00a0al.Disease Modifying Therapies for the Treatment of Transthyretin Amyloid Cardiomyopathy.2024. Draft Evidence Report. Institute for Clinical and Economic Review.https:\/\/icer.org\/assessment\/transthyretin\u2010amyloid\u2010cardiomyopathy\u20102024"},{"key":"e_1_2_9_119_1","unstructured":"VyndaLink: connecting access reimbursement and education.2024. Accessed September 25 2024.https:\/\/www.vyndalink.com\/patient"},{"key":"e_1_2_9_120_1","unstructured":"WainuaWay.2024. Accessed September 25 2024.https:\/\/www.wainua.com\/wainua\u2010way\u2010program"},{"key":"e_1_2_9_121_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.26086"},{"key":"e_1_2_9_122_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2021.3070"},{"key":"e_1_2_9_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2023.131598"},{"key":"e_1_2_9_124_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-021-10080-2"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.4639","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T16:48:53Z","timestamp":1761065333000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.4639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,23]]},"references-count":123,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1002\/phar.4639"],"URL":"https:\/\/doi.org\/10.1002\/phar.4639","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,23]]},"assertion":[{"value":"2024-09-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}